Clinical Applications Of Platelet Rich Plasma

Elham Omar Hamed, Sahar Abo-ElFottohAbdElwahed, Shereen Philip Aziz, Mohamed Hamdy Mahmoud Alrawe, Shimaa Anwar Rashed Ali, NesmaMokhtar Ahmed Mohamed, BedourElsayedHussien.

Departments of Clinical and Chemical Pathology, Faculty of Medicine- Sohag University

Abstract

Background: Platelet-rich plasma (PRP) was beneficial in the department of surgery for 2 many years; there has been modern importance inside the usage of PRP for the therapy of sports-related damages. increase factors and bioactive proteins found in PRP that affect the restoration of tendon, ligament, muscle, and bone. this article studies the main technological know-how of PRP, and it defines the cutting-edge medical makes use of in sports medication and other uses of PRP.

Objective: The goal of the study is to study platelet-rich plasma and its types, to discuss methods of preparations and its clinical applications

Summary: PRP hastens the rate of gentle tissue damage restoration, there are many ability benefits. First, there's a little hazard of rejection due to the fact the injection is from the patient's own autologous blood. 2nd, PRP can be produced in an easy and comparatively cheaper manner instead of the greater complex manner of gathering stem cells.

Conclusion: mainly PRP and items related to PRP have been added to an assorted variety of tissues in a significant number of careful fields. The general point of PRP is to give an incredible focal point of platelet development viewpoints to encourage healing. This present survey proposes that PRP might be valuable in sports medicine

Keywords: Platelet-rich plasma · Endothelial cells · Platelet-poor plasma · Angiogenesis

Introduction

Platelet-rich plasma (PRP) is a platelet-rich concentrate with higher-than-standard degrees of platelets whenever contrasted and entire blood. It is an item subordinate from complete blood through the procedure of evaluation thickness centrifugation **(36).**

There are 2 boss types of PRP, The fundamental one is originated from the plasma layer. It focuses to wipe out red cells and leucocytes from the readiness and to gather the same number of platelets from the lingering "plasma" layer. The auxiliary item is little in erythrocytes and leucocytes have a little measure of platelets (1.5 to multiple times benchmark levels). Another sort of creation is set up from the buffy coat layer. It focuseS to take platelets from both the plasma and the cell layer as is for the most part more noteworthy in platelet volume, making about 3 up to 8 times the standard measure of platelets **(11)**

Our target of the work

The objective of the study to

1. To study platelet-rich plasma, discuss their types.
2. To discuss methods of preparations
3. To discuss its clinical applications

Blood Platelets

Blood platelets are the cells that need nucleus and have a genuine character in the process of hemostasis. In a human body, about 1×10^{11} platelets are shaped each day by a process of

differentiation, development, and discontinuity of the megakaryocytes **(47).**

Every platelet fluctuates in its volume, thickness, and reactivity. The standard platelet includes are in the scope of 150–400×10^9/L. In typical conditions, platelets remain in the blood for 8 up to10 days and when platelet number abatement beneath the ordinary level, the risk of bleeding is incredible **((17)**.

Platelets are little cells yet they are practically significant under hazardous circumstances (**5**) They start from megakaryocytes found in the bone marrow, and circle the blood and kept in the spleen **(25)**

Platelets don't hold a nucleus and when they are in the inactive state they have a discoid shape with a breadth of 2-4 mm **(30,35)** Human beings contain around one trillion blood thrombocytes available for use, everyone has a normal life expectancy of just 8–10 days. Platelets have a significant capacity as they act as the "bandages" of the circulation and react when the vein is harmed by altering their shape, producing their granules, accumulating to create a platelet coagulate. It assumes a fundamental job in aiding and directing angiogenesis and immunity **(3)**

Megakaryocytes are viewed as myeloid cells that found less than 0.1 % of the cell populace of the marrow cells, and their numbers can be influenced by elements as thrombopoietin level (TPO) and chemokines **(4,21).** These develop into burst- and colony-forming units, they both have the CD34 antigen and then continue to mature into megakaryocytes and complete development until they become mature platelet **(29)**

Thrombopoietin level is the best significant controller of thrombopoiesis so platelet sums can be diminished if TPO production is inhibited without harm of the process of hemostasis **(19,41)**

Development of Platelets:-

There are many theories to explain the formation of platelets. In the bone marrow In the bone marrow megakaryocytes situate as a triple structure. With their VEGF production ability, they make the cells of the endothelium of the vessels near themselves**(9).**

The common scientifically known three theories are mentioned as

1) platelet is lightly blebbing from the membrane of megakaryocytes (5)

2) There are cell parts in megakaryocytes named "Demarcation Membrane System" from which platelets granules shrink and trash breaks away (39).

3) The most important hypothesis is "Proplatelet development". as the megakaryocytes have long slender augmentations at the blood flowing site of veins and on these divisions there are minor bodies whereby the help of blood shear power platelets go directly to circulating blood **(16).**

These cell fractions have difficult properties as there is two parts in the cytoplasm could be found in platelets :

1)**Hyalomere**: it is a bright blue uniform area of the outer cytoplasm of the platelet

2)**Granulomere** (**Chromomere**): it is the central region and tight part of the platelets (**44**)

One of the characters of thrombocytes is the great amount of very important active molecules which are present in these granules (**12**)

	Number/ platelet	Diam eter	Surface area/ platelet	Common marker	General function
α - granules	50-80	200-500	14	VWF CXCL4 P-SELECTIN	Homeostasis/thrombosis Inflammation Angiogenesis Host defense Mitogenesis
Dense granules	3-8	150	<1	CD63 serotonin	Homeostasis /thrombosis Inflammation
lysosomes	<3	200-250	<1	Acid phosphatase	Endosomal digestion

Table1: The general features of platelet granule types

(Michelson., 2008)

Platelet role in hemostasis and thrombosis:

Platelet adhesion :

Platelet linkage is a compound procedure happens when a vessel is harmed and result in the cooperation of receptors that are available on the superficial wall of platelets and prompts adherence of platelet to the injured vein (**28).**

Platelet activation :

Platelets are then initiated by this adhesion and by the connection of different platelet agonists to their outer receptors **(42).**

Platelet aggregation :

Platelet aggregation means platelets accumulation to themselves that form a large hemostatic plug that closes the injured blood vessel **(18).**

Platelet-rich plasma :

PRP is known as a section of autologous plasma with a platelet focus higher than the standard degree of the ordinary blood. The best concentration is at minimum a fourfold rise in original concentration or around 1,000,000/mm3 (**23**)

(PRP) have a significant job in the quickening and encouraging reaction to damage. The cellular reaction to damage has four principle phases as the following: hemostasis, inflammation, expansion, lastly remodeling. Each one of these stages is advantaged by better cellular action all of these include platelets. (**35**)

Component of platelet-rich plasma:

Platelets

PRP is characterized by the entire volume of platelets, and not by extra segments of blood. In people, the standard platelet level in absolute blood differed from 150 X 103 up to 350 x 103/μL (13) and platelet-rich plasma is generally known as at any rate 1 x 106 platelet /μL present in the plasma (**24**).

Leukocytes

Leukocytes have a significant capacity as they have and make cytokines that are exact active and cause inflammation. The elevated level of leukocyte is linked with higher production of VEGF **(14)**

Fibrinogen

Fibrinogen cleaved into fibrin monomers by thrombin then they collect into systems of insoluble polymers of fibrin. the platelets, leukocytes, and different cells can multiply, sort out, and execute in a suitable matrix at the site of damage that these systems arrange **(22)**

Growth factors and cytokines

PRP encloses many factors as PRP holds a three to fivefold rise in growth

factor focuses. Important properties in orthopedics as the capacity of anabolic to improve chondrocyte and tenocyte differentiation are. Anabolic growth factors enclosed in PRP as at first; human growth hormone (HGH) then TGF- β1, PDGF, IGF-1, VEGF, and bFGF. also, IGF-1 improves the proliferation of fibroblasts (**8).**

Platelet-Rich Formulations :

There are two main types as following:

Platelet-Rich Plasma (PRP)

It is known as the section of the blood that has a platelet focal point of about one million platelets/μl, or five times greater than that of entire blood (**24**).

Leukocyte-Rich PRP (LR-PRP):

In which PRP has a high count of leukocytes in the blood sample (**15**).

Leukocyte-Poor PRP (LP-PRP):

Leukocyte-poor PRP definitely leukocytes eliminated from the blood section by the aid of cell divider systems that remove them. LP-PRP cannot result in a great inflammatory reaction at 5th days after injection in the intratendinous area compared to LR-PRP (**45**)

Platelet-poor plasma (PPP):

Platelet-poor plasma is considered a creation of the PRP procedure and is the blood section without platelets that is the result after centrifugation to remove erythrocytes from this plasma. Double-spin centrifugation is recommended by some protocols to confirm that platelets are concentrated and enclosed within the PRP. PPP does not contain similar therapeutic benefits as they are deficient in the platelet important factors and cytokines that exist in the PRP **(31).**

Production of PRP :

PRP is set up from any sample of patients' blood drained during treatment. Around 30 ml of blood of veins will return 3up to 5 ml of PRP reliant on the standard platelet volume of the person, the machine and the method that is utilized. An anticoagulant as citrate dextrose is used as the blood flow happens to diminish platelet aggregation before its utilization in non-appropriate concentration **(43).**

Principles of PRP preparation :

PRP is made by a procedure named a differential centrifugation. In which the acceleration power is acclimated to cause sedimentation of some cellular parts dependent on various specific gravity. There are a few strategies for getting ready PRP. It tends to be made by the PRP way or by the buffy-coat way **(25).**

Procedure :

PRP method :

At first, we drain WB in acid citrate dextrose (ACD) tubes

The blood sample can't be chilled at any time during or before platelet separation.

Soft' spin used to Centrifuge the blood, then the supernatant plasma transferred that contains platelets into a different sterilized tube (with no anticoagulation).

Then the tube is centrifuged at a greater level (a hard spin) to acquire the concentrate of the platelet at the end of the tube.

The lower third is PRP but the upper two-thirds is platelet-poor plasma. At the end of the tube, the concentrates are produced. Then PPP removed and the remaining parts suspended in the least amount of plasma (2 up to 4 mL) by then lightly shake the tube (**46**).

Buffy coat method :

1. WB must be put away at 20°C to 24°C preceding centrifugation.
2. At that point, WB is centrifuged at an 'incredible' speed.
3. Three layers are delivered due to differences in their thickness: The last layer made out of RBCs, the center layer named the buffy coat and made out of platelets and WBCs and the upper layer is the PPP layer.

4. At that point supernatant plasma expelled from the highest point of the compartment.
5. At that point move the buffy-coat layer to various sterile tubes.
6. centrifuge at little speed to isolate WBCs **(37)**

Indications :

There are several potential goals for PRP therapy as they can be used in the following :

1. Lateral epicondylitis
2. Medial epicondylitis
3. Rotator cuff pathology
4. Injury of Medial collateral ligament
5. Injury of Lateral collateral ligament
6. Shoulder labrum tear
7. Hip labrum tear
8. Wrist injuries (multiple ligaments and tendons)
9. Biceps tendon partial tear
10. Costochondritis
11. Greater trochanter injury
12. Meniscus injury
13. 13.Patella and quadriceps tendon injuries
14. Achilles tendon (partial tear)
15. Plantar fasciitis
16. Triangular ligament sprains **(32)**

Other applications of PRP:

1)Tendinopathy :

The histological assessment of synovium in osteoarthritic joints uncovers the presence of provocative cytokines in the synovium in agonizing osteoarthritis, the equivalent is absent in chronic tendinopathies (1).

Infusing high measures of platelets into the sites of the incessantly harmed ligament can release numerous important factors through the granules present in the platelet. These GFs, when existing in greater than normal amounts they help the healing response and improve it (**40**)

2) Ligament Pathology

PRGF affect the histological features of tendon grafts, that cause enhanced remodeling in comparison to diseased grafts. Despite the fact that these discoveries are not definitive the usage of PRP in the injured ligament is thought to be harmless, and improved agony and join a rebuilding (**36)**

3)Muscle Pathology

PRP was thought to cause scarring of the muscles. However, more advanced styles in PRP research suggest that they facilitate the muscle strains to heal(**6)**.

PRP can cause a rise in satellite cell enactment, expanded width of recharging fibers, and cause incitement to myogenesis. (**34) .**

5)Platelet-rich plasma in dermatology and aesthetic medicine

Platelet-rich plasma (PRP) is widely used in derma medicine and cosmesis as PRP can be used in the therapy of acne, scars, and hair loss (especially in females). It is also very helpful skin reconstructing and fixing around the eyes. Prior to the injection of PRP in the therapy of hair falling, a modest scalp roller with spikes utilized to stimulate the diminishing regions. **(26)**

6) **Aesthetic and regenerative medicine**

The usage of platelet-rich plasma, which is concentrated blood plasma fulled with platelets, is an essential developing method used in several medical ways as orthopedics, dentistry, surgery or dermatology. PRP (platelet-rich plasma) also used in regenerative and aesthetic medicine. Platelets are the main part of inflammatory cascades because of their major number of cell surface antigens and granules which stock mediators that have the main function (2) 7) **Ulcers in patients with DM :**

A diabetic foot ulcer is the main complication effect of 15% of patients who suffer from DM type 2. Progressing tissue destruction can cause such advanced damage, an amputation might be the only available treatment. Treatment is long-term and complicated, and achieving good

therapeutic effects is difficult. Treatment is based on disinfection, surgery and enzymatic substances, PRP usage during the therapy of these ulcers will enhance the response and improve the healing procedure (7**).**

Basic Concerns and Contraindications for PRP :

1. Immunocompromised patients are conceivably at high hazard for disease
2. Patients with thrombocytopenia or bleeding issue
3. Persons who experience the ill effects of dynamic malignant growth
4. History of malignant growth or suspected oncological malady must counsel with an oncologist and get medicinal leeway before treatment with PRP,
5. Fundamental or confine Infection is consistently an essential worry in playing out any interventional procedure
6. Coagulopathy due to platelet disorder, Complicated and unpredictable life systems,
7. Consistent treatment with NSAID or steroid treatment,
8. Patient refusal or powerlessness to give educated assent
9. Increased agony at the infusion position.
10. Increased incendiary response at the treatment site from the injectate...
11. Proper naming for tests and legitimate transfer ought to be utilized to counteract cross-tainting, particularly if numerous patients are being dealt with (**33,38**)

Patient selection for PRP injection :

There are a few perspectives that influence the outcome as age, seriousness of ligament degeneration or knee osteoarthritis, length of side effects, earlier therapeutic meditations, and patient activity level may all be viewed as when assessing a patient for the use of PRP**(20**)

Patient preparation :

Patients should experience a careful physical test to affirm knee OA and evaluate delicate periarticular torment generators that can be incorporated into treatment. Dangers and advantages must be inspected with the patient, and composed assent is accomplished **(10).**

Technique :

The patient is put prostrate with slight flexion of his knee. With the sonar guide and utilizing a lateral methodology, PRP is brought into the area of supra patella bursa **(13).**

Post-procedure care

After an infusion, patients are educated to escape from Jacuzzis or hot tubs and pools for the initial 24–48 h to diminish contamination hazard. **(43)**

Conclusion

Platelet-rich plasma (PRP might be known as the autologous part of plasma with platelet focus surpassing the standard level. Studies have shown that the best concentration is at the minimum rise in original concentration, or around 1,000,000/mm3

There are 2 boss sorts of PRP prepared. The first is from the plasma layer. Its objective is barring red and white cells from the readiness and to collect a few platelets from the rest of the "plasma" layer as plausible. The outcome generation is little in red and white cells and has a somewhat level of platelets (1.5 to multiple times standard levels). The second kind of item is delivered from the buffy coat layer. Its objective is to take platelets from both the plasma and the cell layer as is commonly more noteworthy in platelet check, yielding roughly 3 to multiple times the standard degree of platelets

References

1. Adams Jr SB, Setton LA and Kensicki E. (2012): Global metabolic profiling of human osteoarthritic synovium. Osteoarthritis Cartilage.;20:64–7.

2. Akingboye AA., Giddins S, Gamston P, Tucker A, Navsaria H and Kyriakides C. (2010): Application of autologous derived-platelet rich plasma gel in the treatment of chronic wound ulcer: diabetic foot ulcer., J Extra Corpor Technol., 42(1), 20-9

3. Anitua, E., Sanchez, M., Nurden, A.T., Nurden, P., Orive, G. and Andia, I.(2006): New insights into and novel applications for platelet-rich fibrin therapies. Trends Biotechnol., 24, 227–234.

4. Avecilla ST, Hattori K, Heissig B, Tejada R, Liao F, Shido K, Jin DK, Dias S, Zhang F, Hartman TE, Hackett NR, Crystal RG, Witte L, Hicklin DJ, Bohlen P, Eaton D, Lyden D, de Sauvage F and Rafii S (2004) :Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nat Med 10:64–71

5. Becker RC(2008): Platelet Biology: The Role of Platelets in Hemostasis, Thrombosis, and Inflammation. Platelets in Cardiovascular Disease. In: Bhatt DL. Imperial College Press. London:1-3.

6. Bubnov R, Yevseenko V and Semeniv I.(2013): Ultrasound-guided injections of platelets rich plasma for muscle injury in professional athletes. Comparative Study Med Ultrasound.;15:101–5.

7. Castillo TN, Pouliot MA, Kim HJ and Dragoo JL (2011): Comparison of growth factor and platelet concentrations from commercial platelet-rich plasma separation systems. Am J Sports Med 39:266–271

8. Dressing S, Holm L, Heinemeier KM, Feldt-Rasmussen U, Schjerling P and Qvortrup K. (2010): Disorders pathophysiology positively associated with musculotendinous collagen expression: experiments in acromegalic and GH deficiency patients. Eur J Endocrinol; 163(6):853–62.

9. Drouin A, Cramer EM, Gresele P, Page CP, Fuster V and Vermylen J. (2008): Platelets in Thrombotic and Non-Thrombotic, pharmacology and therapeutics. Journal of Thrombosis and Haemostasis, 1(3), 613-614.

10. Filardo G, Kon E, Di Martino A, Di Matteo B, Merli ML and Cenacchi A. (2012): Platelet-rich plasma vs hyaluronic acid to treat knee degenerative pathology: study design and preliminary results of a randomized controlled trial. BMC Musculoskelet Disord.;13:229–2474-13-229.

11. Fitzpatrick J, Bulsara M. K. and Zheng M. H.(2017): The Effectiveness of Platelet-Rich Plasma in the Treatment of Tendinopathy: A Meta-analysis of Randomized Controlled Clinical Trials. The American Journal of Sports Medicine, 2017; Vol. 45, No. 1

12. Flaumenhaft R (2003): Molecular basis of platelet granule secretion.ArteriosclerThrombVascBiol 23:1152–1160

13. Foster TE, Puskas BL, Mandelbaum BR, Gerhardt MB and Rodeo SA (2009): Platelet-rich plasma: from basic science to clinical applications. Am J Sports Med.;37(11):2259–72.

14. Freeman MR, Corless C, Gagnon ML, Soker S, Niknejad K and Schneck FX (1995): Peripheral blood T lymphocytes and lymphocytes infiltrating human malignancy express vascular endothelial growth factor: a potential role for T cells in angiogenesis. Cancer Res. 1995;55(18):4140–5.

15. Hartwig JH and Italiano JE Jr (2006): Cytoskeletal mechanisms for platelet production. Blood Cells Mol Dis 36:99–103

16. Italiano JE Jr and Shivdasani RA.(2003): Megakaryocytes and beyond: the birth of platelets. J Thromb Haemost;1(6):1174-82.

17. Jones CI, Kawachi I and Lassmann H .(2016):Platelet function and aging.Neurodegeneration in multiple sclerosis and neuromyelitis optic. J Neurol Neurosurg Psychiatry 27: 358–366.

18. Jurk K. and Kehrel B.E. (2005): Platelets: physiology and biochemistry. Semin.Thromb.Hemost.31, 381–392.

19. Kaushansky K (2006): Lineage-specific hematopoietic growth factors. N Engl J Med 354:2034–2045

20. Kon E, Mandelbaum B, Buda R, Filardo G, Delcogliano M and

Timoncini A. (2011): Platelet-rich plasma intra-articular injection versus hyaluronic acid viscosupplementation as treatments for cartilage pathology: from early degeneration to osteoarthritis. Arthroscopy.;27(11):1490–501.

21. Larson MK and Watson SP (2006): A product of their environment: do megakaryocytes rely on extracellular cues for proplatelet formation? Platelets 17:435–440

22. Laurens N, Koolwijk P and de Maat MP.(2006): Fibrin structure and wound healing. J Thromb Haemost;4(5):932–9.

23. Garg A and Marx R (2005): Dental and craniofacial applications of platelet-rich plasma. Quintessence Publishing Company.

24. Marx RE (2001): Platelet-rich plasma (PRP): what is PRP and what is not PRP? Implant Dent; 10(4):225–8.

25. Mason KD, Carpinelli MR, Fletcher JI, Collinge JE, Hilton AA, Ellis S, Kelly PN, Ekert PG, Metcalf D, Roberts AW, Huang DC and Kile BT.(2007): Programmed anuclear cell death delimits platelet life span. Cell.;128(6):1173-86.

26. Mehta S and Watson JT.(2008): Platelet-rich concentrate: basic science and current applications. J Orthop Trauma.;22:432-8.

27. Michelson AD (2008): Thrombin-induced down-regulation of the platelet membrane glycoprotein Ib-IX complex. SeminThrombHemost 18:18–27

28. Nieswandt, B., Varga-Szabo, D. and Elvers, M.(2009): Integrins in platelet activation. J. Thromb. Haemost.7, 206–209.

29. Ogawa M (1993): Differentiation and proliferation of hematopoietic stem cells. Blood 81:2844–2853

30. Ovalle WK and Nahirney PC.(2007): Netter Essential Histology. Saunders;166., pp.311-32.

31. Pietrzak WS, Kang QK, An YH, Demos HA and Ehrens KH (2007): Platelet-rich and platelet-poor plasma: development of an animal model to assess hemostatic efficacy. J Craniofac Surg. 2007;18(3):559–67.

32. Rabago D, Best TM, Zeisig E, Zgierska AE, Ryan M and Crane D.(2009): A systematic review of four injection therapies for lateral epicondylosis, polidocanol, whole blood, and platelet-rich plasma. Br J Sports Med;43:471–81

33. Reeves K. (2007): Prolotherapy: regenerative injection therapy. In: Waldman S, editor. Pain management.Philadelphia: Saunders. p. 1106–27.

34. Reurink G, Goudswaard GJ and Moen MH.(2015): Rationale, secondary outcome scores and 1-year follow-up of a randomized trial of platelet-rich plasma injections in acute hamstring muscle injury: the Dutch Hamstring Injection Therapy study. Br J Sports Med.

35. Rozman P and Bolta Z.(2007): Use of platelet growth factors in treating wounds and soft-tissue injuries. ActaDermatovenerol Alp Panonica Adriat.;16(4):156-65.

36. Sanchez M, Fiz N, Azofra J, Usabiaga J, AdurizRecalde E and Garcia Gutierrez A.(2012): A randomized clinical trial evaluating plasma rich in growth factors (PRGF-Endoret) versus hyaluronic acid in the short-term treatment of symptomatic knee osteoarthritis. Arthroscopy.;28(8):1070–8.

37. Scherer SS, Tobalem M, Vigato E, Heit Y, Modarressi A and Hinz B.(2012): Non-activated versus thrombin-activated platelets on wound healing and fibroblast-to-myofibroblast differentiation in vivo and in vitro. PlastReconstrSurg. ;129:46e–54e.

38. Schilephake H.(2002): Bone growth factors in maxillofacial skeletal reconstruction. Int J OralMaxillofac Surg.;31:469–84.

39. Schulze H, Korpal M, Hurov J, Kim SW, Zhang J, Cantley LC, Graf T and Shivdasani RA.(2006): Characterization of the megakaryocyte demarcation membrane system and its role in thrombopoiesis. Blood.;107(10):3868-75.

40. Spakova T, Rosocha J, Lacko M, Harvanova D and Gharaibeh A. (2012): Treatment of knee joint osteoarthritis

with autologous platelet-rich plasma in comparison with hyaluronic acid. Am J Phys Med Rehabil;91(5):411–7.

41. Tucker EI, Marzec UM, Berny MA, Hurst S, Bunting S, McCarty OJ, Gruber A and Hanson SR (2010): Safety and antithrombotic efficacy of moderate platelet count reduction by thrombopoietin inhibition in primates. SciTransl Med 2:37ra45

42. Wallace, E., and Smyth, S. (2013): Targeting Platelet Thrombin Receptor Signaling to Prevent Thrombosis. Pharmaceuticals, 6(8), 915–928

43. Wang- A, Cugat R, Seijas R, Ares O, Cusco X, and Garcia- Balletbo M. (2011); Infiltration of plasma rich in growth factors for osteoarthritis of the knee short-term effects on function and quality of life. Arch Orthop Trauma Surg.;131(3):311–7.

44. Weibrich G, Kleis WK, Hafner G and Hitzler WE.(2002): Growth factor levels in platelet-rich plasma and correlations with donor age, sex, and platelet count. J Craniomaxillofac Surg;30(2):97–102.

45. Weibrich G, Kleis WK, Hitzler WE and Hafner G.(2005): Comparison of the platelet concentrate collection system with the plasma-rich- an in-growth-factors kit to produce platelet-rich plasma: a technical report. Int J Oral Maxillofac Implants. ;20(1):118–23.

46. Welsh WJ.(2000): Autologous platelet gel: Clinical function and usage in plastic surgery. Cosmetic Derm;11:13–9